Nuclea has developed a number of pan antibodies that greatly simplify and accelerate the drug discovery processes in the tyrosine kinase (TK) disciplines. TK's are the most popular targets for new drug discovery in the oncology arena with significant advances in both genomics and proteomics. Thus, it makes possible the rapid identification of proteins that play significant roles in disease, many of which will become novel drug targets or diagnostic markers. Patents Pending
• Is analogous to the Pan-Phosphoprotein (PS/PT/PY) antibody that
recognizes any protein that is phosphorylated on the serine, threonine,
or tyrosine residues.
• Can be used for both Immunoprecipitations and Western Blots.
• Of interest to any research lab working with Eph receptors, VEGFr,
or the aforementioned proteins will be interested in this antibody.
• Is analogous to the Pan-Phosphoprotein (MAPKAP) antibody that recognizes
any protein that is phosphorylated on the serine, threonine, or tyrosine
residues.
• Can be used for both Immunoprecipitations and Western Blots.
• Of interest to any research lab working with Rsk receptors, Histone
H3 or the aforementioned proteins will be interested in this antibody.
• Is analogous to the Pan-Phosphoprotein (PI3) antibody that recognizes
any protein that is phosphorylated on the serine, threonine, or tyrosine
residues.
• Can be used for both Immunoprecipitations and Western Blots.
• Of interest to any research lab working with any PI3 Kinase receptor
or the aforementioned proteins will be interested in this antibody.
Nuclea has developed a proprietary technology which helps to identify protein or peptide biomarkers of disease directly from whole tissue samples, a process that is still highly valuable despite significant advances in both genomics and proteomics. By combining proteomics methodologies with high-throughout genomic analysis, this technology eliminates the need for protein purification and greatly increases efficiency. Thus, it makes possible the rapid identification of proteins that play significant roles in disease, many of which will become novel drug targets or diagnostic markers. Patents Pending
The gene expression profiles will be run using the Affymetrix Human GeneChip arrays. The Affymetrix GeneChip® represents the most universally used gene arrays and comprehensive data sets available to the scientific community. The initial Gene Expression Database offering will consist of the Human Genome U133 Plus 2 Array. This array has over 47, 000 transcripts. These were selected from GenBank®, dbEST and RefSeq data sets. These provide the most comprehensive data sets for the entire human transcriptome and as such, make the use of the U133 Plus 2A an invaluable tool for the direct analysis of the gene expression from any tissue.
The Human Genome CGH Microarray (G2519A) (by Agilent) provides genome-wide coverage with an emphasis on the most commonly studied genomic coding regions and cancer-related genes. It includes 40,000 probes that span the human genome with an average spatial resolution of approximately 75 kb, including coding and noncoding sequences. It includes one probe per gene for RefSeq and Genbank Known Genes and three probes for each of approximately 1,100 known cancer genes of importance. The remaining probes are distributed to cover the rest of the genome, with an emphasis on less well known and predicted gene sequences from public databases.
Designed specifically for CGH experiments, this microarray delivers CGH performance superior to microarrays designed for gene expression. Using 60-mer oligonucleotide probes, the microarray provides very high sensitivity, enabling researchers to reliably identify both highly localized and broadly extended single copy deletions, homozygous gene deletions and amplicons. The gene-focused content of the CGH array facilitates comparison of CGH and gene expression data so that researchers can correlate genomic copy number changes with gene expression changes.
The array-CGH solution requires only 25 nanograms of total genomic DNA to detect chromosomal changes across the entire genome. By comparison, scientists using other oligo microarrays have typically needed to use 10
times more DNA and significantly reduce the complexity of their genomic samples, usually by amplifying only specific DNA regions. The use of total genomic DNA improves experimental design and ease of use.
The mechanism of cancer progression involves chromosomal aberrations, including amplification of oncogenes and deletion of tumor suppressor genes. Microarray-based comparative genomic hybridization (array-CGH) is uniquely well suited for high-resolution detection of DNA copy number aberrations. This technology features a database of array-CGH data focused on genomic alterations in human and mouse cancer genomes. This database contains cancer profiles of melanoma, glioblastoma multiforme, multiple myeloma, pancreatic adenocarcinoma colon adenocarcinoma, breast adenocarcinoma, Prostate adenocarcinoma and lung adenocarcinoma.
Since chromosomal aberrations play a pivotal role in cancer progression, knowledge of these genetic imbalances promises to lead to improved cancer diagnoses and treatments. These chromosomal aberrations are best revealed via array-CGH analysis. Array-CGH provides high-resolution estimates of copy aberrations, and can be performed efficiently on many samples. The data provided by array-CGH are quantitative measures of the DNA sequence dosage increase. Moreover, array-CGH can be performed with primary tumor tissue, circumventing issues with tumor cell cultures.
Nuclea Biomarkers, LLC., is pleased to offer to our Pharmaceutical and Biotechnology customers access to the Nuclea arrayCGH/ Gene Expression Profile Product line. We can provide matched Tissue Microarrays (TMA) consisting of the exact samples used in the gene expression studies. These TMAs allow for localization of selected proteins as well as for antibody target characterization through immunohistochemistry studies. This unique combination of services provides answers to the basic biological questions of:
• What genes are expressed in these tissues?
• Is there a difference in the expression pattern of disease vs. normal tissues?
• Are the proteins expressed in a coordinated manner as the mRNA?
• What is the cellular localization of these proteins?
• Can I characterize my antibody of choice in terms of mRNA and protein expression?
Through the use of combined Gene Expression Profile and the matched TMA, the answer to these and many more important questions can be addressed.
Custom Gene Expression Profiles.
Through access to our extensive partners, Nuclea offers gene expression data on selected tissues. As the client, you will pick which tissues, based on tissue type, disease, demographics and clinical data, best serves to provide the answers to you need solutions for. Nuclea will prepare and run the samples through our Gene Expression Profile group. The data will be provided in the GeneChip® Operating System format to for ease of data analysis. By providing the complex gene expression data in its direct form, Nuclea., will not be introducing any inherit biases to the data nor hindering its analysis. The researcher will be able to perform their own data analysis using their preferred software packages or their own in-house programs. Nuclea, feels this provides the best all around answer to the question of data analysis. Also, by providing the data in this form, Nuclea, has reduced the cost of the data generation and thus allowing the customer the ability to perform additional gene expression experiments without any hidden costs.
Starter Sets - 50ug
Antibody
Full Antibody-300ug
Antibody
Custom Aliquots
Please
Nuclea Biomarkers, LLC
105 South St.
Pittsfield, MA 01201
Phone: 413-749-4705
Fax: 413-445-9930
